Top Markets
#1 Black Phoenix Black Phoenix +166.82%
#2 Islamic Coin Islamic Coin +158.16%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +29.06%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +18.86%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.84%
#8 Test Test +13.79%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +10.94%
#10 Bluwhale Bluwhale +10.65%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
InNexus Biotechnology, Inc. InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc.

IXSBF
Rank in Stocks #41696
InNexus Biotechnology, Inc. is a development-stage company dedicated to... InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.
Share Price
$0.0001
Last synced: 2025-11-07
Market Cap
$12.63K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade InNexus Biotechnology, Inc. (IXSBF)

Category

Healthcare
Operating Margin for InNexus Biotechnology, Inc. (IXSBF)
Operating Margin as of 2026 TTM: 0.00%
According to InNexus Biotechnology, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for InNexus Biotechnology, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
67.93% -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
0.00% -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
0.00% -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
0.00% -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
0.77% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.